^
    5d
    A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=110, Active, not recruiting, Cogent Biosciences, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    FGFR2 (Fibroblast growth factor receptor 2)
    |
    CGT4859
    28d
    A Monotherapy in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=42, Active, not recruiting, 3D Medicines (Beijing) Co., Ltd. | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial primary completion date
    |
    segigratinib (3D185)
    1m
    Safety and Efficacy of Voxzogo for Growth Deficits in MPS IVA and VI (clinicaltrials.gov)
    P1/2, N=6, Active, not recruiting, University of California, San Francisco | Trial completion date: Dec 2026 --> Dec 2029 | Trial primary completion date: Dec 2025 --> Dec 2028
    Trial completion date • Trial primary completion date
    2ms
    Design, synthesis, and Lead optimization of novel Quinazoline-based FLT3 inhibitors with potent anti-acute myelogenous leukemia activity. (PubMed, Bioorg Med Chem Lett)
    Guided by a scaffold-hopping strategy based on G-749 (denfivontinib), a series of quinazoline-based derivatives was designed and synthesized to explore structure-activity relationships (SAR)...Mechanism studies indicated that W4 induced G0/G1 cell cycle arrest and apoptosis, accompanied by a reduction in intracellular reactive oxygen species levels and a loss of mitochondrial membrane potential. Collectively, these results identified W4 as a potent FLT3 inhibitor and provided valuable SAR insights for further scaffold optimization.
    Journal
    |
    FLT3 (Fms-related tyrosine kinase 3) • KIT (KIT proto-oncogene, receptor tyrosine kinase)
    |
    FLT3 mutation
    |
    denfivontinib (SKI-G-801)
    2ms
    ASPEN: A Phase 2/3 Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia (clinicaltrials.gov)
    P2/3, N=160, Not yet recruiting, BioMarin Pharmaceutical
    New P2/3 trial
    2ms
    TYR300-202: A multicenter, open-label, Phase 2 study of TYRA-300 in non-muscle invasive bladder cancer (2025-521277-14-00)
    P1/2, N=48, Recruiting, Tyra Biosciences Inc.
    New P1/2 trial
    |
    FGFR3 mutation
    |
    dabogratinib (TYRA-300)
    2ms
    111-212: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Vosoritide in Infants and Young Children with Hypochondroplasia, Aged 0 to < 36 Months (2024-512261-14-00)
    P1/2, N=30, Recruiting, Biomarin Pharmaceutical Inc.
    New P1/2 trial
    2ms
    111-308: Long-Term Extension Study of Vosoritide to Treat Children with Hypochondroplasia (2024-517238-16-00)
    P2/3, N=44, Recruiting, Biomarin Pharmaceutical Inc.
    New P2/3 trial
    3ms
    SURF303: Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma (clinicaltrials.gov)
    P2, N=230, Recruiting, Tyra Biosciences, Inc | Not yet recruiting --> Recruiting
    Enrollment open
    |
    FGFR3 (Fibroblast growth factor receptor 3)
    |
    dabogratinib (TYRA-300)
    3ms
    SURF301: Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations (clinicaltrials.gov)
    P1/2, N=310, Active, not recruiting, Tyra Biosciences, Inc | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    FGFR3 mutation
    |
    dabogratinib (TYRA-300)
    4ms
    HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma (clinicaltrials.gov)
    P2/3, N=235, Recruiting, Hutchmed | Phase classification: P2 --> P2/3 | N=128 --> 235 | Trial completion date: Dec 2025 --> Feb 2030 | Trial primary completion date: Jun 2025 --> Jun 2028
    Phase classification • Enrollment change • Trial completion date • Trial primary completion date
    |
    FGFR2 (Fibroblast growth factor receptor 2)
    |
    FGFR2 fusion
    |
    fanregratinib (HMPL-453)
    4ms
    A Study of ABSK061 to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy in Children With Achondroplasia (clinicaltrials.gov)
    P1/2, N=110, Not yet recruiting, Abbisko Therapeutics Co, Ltd
    New P1/2 trial
    |
    lavengratinib (ABSK061)